KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

NovoCure (NVCR) Other Operating Expenses (2016 - 2025)

NovoCure (NVCR) has disclosed Other Operating Expenses for 12 consecutive years, with $68.7 million as the latest value for Q4 2025.

  • Quarterly Other Operating Expenses rose 1.85% to $68.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $240.1 million through Dec 2025, changed 0.42% year-over-year, with the annual reading at $240.1 million for FY2025, 0.42% changed from the prior year.
  • Other Operating Expenses hit $68.7 million in Q4 2025 for NovoCure, up from $58.5 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $68.7 million in Q4 2025 to a low of $31.4 million in Q1 2021.
  • Historically, Other Operating Expenses has averaged $50.8 million across 5 years, with a median of $55.5 million in 2024.
  • Biggest five-year swings in Other Operating Expenses: surged 40.03% in 2023 and later fell 3.2% in 2024.
  • Year by year, Other Operating Expenses stood at $39.0 million in 2021, then increased by 27.31% to $49.6 million in 2022, then increased by 19.26% to $59.2 million in 2023, then grew by 13.89% to $67.4 million in 2024, then increased by 1.85% to $68.7 million in 2025.
  • Business Quant data shows Other Operating Expenses for NVCR at $68.7 million in Q4 2025, $58.5 million in Q3 2025, and $57.1 million in Q2 2025.